Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Express Scripts
Boehringer Ingelheim
McKesson
Merck

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Litigation Details for ELI LILLY AND COMPANY v. SICOR PHARMACEUTICALS, INC. (S.D. Ind. )

See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in ELI LILLY AND COMPANY v. SICOR PHARMACEUTICALS, INC.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for ELI LILLY AND COMPANY v. SICOR PHARMACEUTICALS, INC. (S.D. Ind. )

Date Filed Document No. Description Snippet Link To Document
2007-04-27 125 1 The patents at issue are U.S. Patent Nos. 4,808,614 and 5,464,826. Compl. ¶¶ 11…gemcitabine would not infringe upon Lilly’s patents and that said patents are invalid. Defs.’ Mem. at 5-6. …ANDAs, and therefore also infringed upon Lilly’s patents.2 On May 12, 2006, Defendants filed this…time frame after being notified of the potential patent infringement. The California …Circuit law governs personal jurisdiction issues in patent infringement cases. See Hildebrand v. Steck External link to document
2010-03-31 375 4,808,614 (“the ’614 patent”) and 5,464,826 (“the ’826 patent”). The ’614 patent covers the compound … of the ’614 patent: Watamane (1979 (PTX-587); U.S. Patent No. 4,211,733 (“’773 patent”); the Bergstrom…the original patent application ultimately leading to the ’826 patent, the second patent-in-suit. Specifically… ’614 patent and the ’826 patent are invalid for obviousness. Under the United States Patent Act, …infringement of two patents held by Plaintiff Eli Lilly and Company (“Lilly”): United States Patent Nos. 4,808,614 External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
McKinsey
Harvard Business School
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.